- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: GA-101 | GA101 | Gazyva®
obinutuzumab is an approved drug (FDA (2013), EMA (2014))
Compound class: Antibody
Comment: Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
View more information in the IUPHAR Pharmacology Education Project: obinutuzumab
|In vitro, obinutuzumab induces cell death and antibody-dependent cell-mediated cytotoxicity (ADCC) more effectively than the original type I anti-CD20 antibodies rituximab and ofatumumab . In vivo, obinutuzumab induces a strong antitumour effect .
However, we have been unable to find affinity data for this antibody from any open access source.
|Selectivity at other protein targets|
|Key to terms and symbols||Click column headers to sort|